Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis: Randomised Prospective Study.

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519126-20-00

Acronym

2019_0012

Enrollment

180

Registered

2024-11-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, adenomyosis

Brief summary

The primary evaluation criterion is the clinical pregnancy rate (confirmed by the presence of a fetal heartbeat), which will be assessed in both groups during the ultrasound conducted at the final visit

Detailed description

Number of successful implantations per number of embryos transferred;, Miscarriage defined as a spontaneous pregnancy loss after a successful implantation;, Incidence and severity of side effects related to hypoestrogenism (e.g., hot flashes, night sweats, decreased libido, mood swings, etc.)

Interventions

DRUGDECAPEPTYL L.P. 11

DRUG25 mg

DRUGpoudre et solvant pour suspension injectable (IM ou SC) forme à libération prolongée sur 3 mois

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary evaluation criterion is the clinical pregnancy rate (confirmed by the presence of a fetal heartbeat), which will be assessed in both groups during the ultrasound conducted at the final visit	—

Secondary

Measure	Time frame
Number of successful implantations per number of embryos transferred;, Miscarriage defined as a spontaneous pregnancy loss after a successful implantation;, Incidence and severity of side effects related to hypoestrogenism (e.g., hot flashes, night sweats, decreased libido, mood swings, etc.)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026